Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
Oral presentation on an efficacy study conducted in Japanese patients comparing anaphylaxis symptoms during oral food challenge with neffy as the initial treatment compared to site historical data on
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
01:04am, Thursday, 06'th Feb 2025
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy's early sales also beat expectations, which I think showcases how mu
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
02:22pm, Monday, 13'th Jan 2025
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
08:00am, Monday, 06'th Jan 2025
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
05:25pm, Thursday, 19'th Dec 2024
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
02:32pm, Thursday, 12'th Dec 2024
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies Licensing partners in key Asia Pacific countries have filed fo
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® ( epinephrine nasal spray) 2mg for use in emergency treatment of
ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript
12:40pm, Wednesday, 13'th Nov 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Alex Straus - Investor Relations Richard Lowenthal - Co-Founder, President a
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates
08:40am, Wednesday, 13'th Nov 2024
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.16 per share a year ago.
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
06:30am, Wednesday, 13'th Nov 2024
Commercial launch of neffy ® (epinephrine nasal spray) underway in the United States Supplemental NDA for neffy ® 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025 Exc
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY.
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
05:30pm, Saturday, 09'th Nov 2024
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exc
Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet
10:55am, Wednesday, 06'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 67.6% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questi
ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
11:00am, Monday, 04'th Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceut
